Goldman Sachs analyst David Roman lowered the firm’s price target on Boston Scientific (BSX) to $112 from $124 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s AXIOS™ Gastroenterostomy Trial Paused: What Investors Should Watch
- Boston Scientific’s RAINBOW Study: What the Hot AXIOS™ Update Means for Investors
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Boston Scientific price target lowered to $112 from $113 at Evercore ISI
- Boston Scientific’s Global Pulsed Field Ablation Trial Targets Persistent Atrial Fibrillation Growth